Literature DB >> 24720539

Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription.

Aiko Kida, Michael Kahn1.   

Abstract

Hypoxia has been reported to regulate both stem cell maintenance and differentiation. Wnt signaling is also a key regulator in stem cells. The recent discovery of functional cross-regulation between the Wnt pathway and HIF-1α/HIF-2α signaling further highlights the complexity of the role of hypoxia in the regulation of stem cells. In this report we reveal that human CML cell lines treated under hypoxic conditions increase the percentage of leukemia stem/initiating-like cells, as judged by surface marker expression, colony forming ability and quiescence. We demonstrate that differential usage of the Kat3 coactivators, CREBBP/Creb Binding Protein (CBP) and EP300 (p300) by catenin, with increased CBP/catenin signaling at the expense of p300/catenin signaling, is mechanistically correlated with the increase in the leukemia stem/initiating-like population. A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24720539     DOI: 10.2174/1874467207666140219121219

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  13 in total

Review 1.  CBP/Catenin antagonists: Targeting LSCs' Achilles heel.

Authors:  Yong-Mi Kim; Eun-Ji Gang; Michael Kahn
Journal:  Exp Hematol       Date:  2017-05-04       Impact factor: 3.084

2.  Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Authors:  Xuejie Jiang; Po Yee Mak; Hong Mu; Wenjing Tao; Duncan H Mak; Steven Kornblau; Qi Zhang; Peter Ruvolo; Jared K Burks; Weiguo Zhang; Teresa McQueen; Rongqing Pan; Hongsheng Zhou; Marina Konopleva; Jorge Cortes; Qifa Liu; Michael Andreeff; Bing Z Carter
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

Review 3.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 4.  Histone modifications: Targeting head and neck cancer stem cells.

Authors:  John M Le; Cristiane H Squarize; Rogerio M Castilho
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

Review 5.  Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications.

Authors:  Ritama Paul; Jay F Dorsey; Yi Fan
Journal:  Pharmacol Ther       Date:  2021-09-01       Impact factor: 12.310

Review 6.  CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.

Authors:  Michael Bordonaro; Darina L Lazarova
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 7.  Targeting the canonical Wnt/β-catenin pathway in hematological malignancies.

Authors:  Eishi Ashihara; Tetsuya Takada; Taira Maekawa
Journal:  Cancer Sci       Date:  2015-04-01       Impact factor: 6.716

8.  Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism.

Authors:  Zuzana Rychtarcikova; Sandra Lettlova; Veronika Tomkova; Vlasta Korenkova; Lucie Langerova; Ekaterina Simonova; Polina Zjablovskaja; Meritxell Alberich-Jorda; Jiri Neuzil; Jaroslav Truksa
Journal:  Oncotarget       Date:  2017-01-24

9.  Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance.

Authors:  Andrea Bild; Jia-Ling Teo; Michael Kahn
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 10.  Safely targeting cancer stem cells via selective catenin coactivator antagonism.

Authors:  Heinz-Josef Lenz; Michael Kahn
Journal:  Cancer Sci       Date:  2014-09-06       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.